Integrated HIV Care and Service Engagement among People Living with HIV who Use Drugs in a Setting with a Community-Wide Treatment as Prevention Initiative

It is well known that social and structural inequities, such as poverty and homelessness, can create barriers to routine HIV care among people living with HIV (PLHIV) who use drugs. Such barriers can contribute to poor HIV-related health outcomes among PLHIV who use drugs and undermine HIV treatment and prevention strategies. In British Columbia, treatment is offered universally upon diagnosis with HIV, as part of province-wide Treatment as Prevention (TasP) strategy.

Citation: Collins, A., Parashar, S., Hogg, R., Fernando, S., Worthington, C., McDougall, P., Baltzer Turje, R., & McNeil, R. (2017). Integrated HIV care and service engagement among people living with HIV who use drugs in a setting with a community-wide treatment as prevention initiative: a qualitative study in Vancouver, Canada. Journal of the International AIDS Society, 20(1).

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below